Luxembourg's financial regulator, the Commission de Surveillance du Secteur Financier (CSSF) has announced that on 20 August 2015, 15 September 2015, 23 October 2015 and 3 December 2015, Omega Pharma Invest NV (registered with the CSSF under the issuer number E-1058) was fined by the CSSF according to Article 25(1) of the law of 11 January 2008 on transparency requirements for issuers of securities.
The CSSF noticed that the issuer in question failed to act in response to orders of the CSSF and did not comply with the CSSF’s request for information, in relation to
- the CSSF’s right to examine that periodic information referred to in the Transparency Law is drawn up in accordance with the relevant reporting framework and take appropriate measures in case of discovered infringements, as per Article 22(2)(h) of the Transparency Law;
- the issuer’s failure to comply with some requirements of Article 3 of the Transparency Law, in relation to its management report and the statements made by the persons responsible within the issuer.
Moreover, the CSSF requested, in accordance with Article 22(2)(d) of the Transparency Law, the suspension from trading on the regulated market of the securities issued by Omega Pharma Invest NV. In accordance with the before-mentioned article, this suspension has been requested for a maximum of ten days and will be renewed until Omega Pharma Invest NV will have complied with all the above-mentioned requirements of the Transparency Law.
According to Article 27 of the Transparency Law, a court action against the administrative fines may be lodged by the issuer with the Tribunal administratif (Administrative Court) within three months by an attorney-at-law registered at the Bar of Luxembourg or at the Bar of Diekirch.
These sanctions, together with the other measures mentioned above, are disclosed according to Article 25(2) of the Transparency Law.
